Evidence map›Paper›PMID 27626678›Full record

ArticleOncotarget2016

Identification of a new class of WNT1 inhibitor: Cancer cells migration, G-quadruplex stabilization and target validation.

Lien-Cheng Chang, Tsung-Chih Chen, Shiag-Jiun Chen, Chun-Liang Chen, Chia-Chung Lee, Shih-Hsiung Wu, Yun Yen, Hsu-Shan Huang, Jing-Jer Lin

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Targeting the Wnt signaling pathway for breast cancer bone metastasis therapy.Journal of molecular medicine (Berlin, Germany) · 2022
    Review
  4. Wnt/β-catenin signaling in cancers and targeted therapies.Signal transduction and targeted therapy · 2021
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Lien-Cheng ChangInstitute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei 112, Taiwan, ROC.
Tsung-Chih ChenGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan, ROC.
Shiag-Jiun ChenSchool of Pharmacy, National Defense Medical Center, Taipei 114, Taiwan, ROC.
Chun-Liang ChenGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan, ROC.
Chia-Chung LeeGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan, ROC.
Shih-Hsiung WuInstitute of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan, ROC.
Yun YenGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan, ROC.
Hsu-Shan HuangGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan, ROC.
Jing-Jer LinInstitute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei 112, Taiwan, ROC.
Taipei Medical University · TWNational Defense Medical Center · TWNational Yang Ming Chiao Tung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developing the Wnt pathway inhibitors has been considered as a therapeutic approach for cancers and other Wnt-related diseases. Previously we found that the G-rich sequence of WNT1 promoter is capable of forming G-quadruplex structure and stabilizing agents for Wnt1-mediated signaling pathway. Using a established cell-based drug screen system that enabled the evaluation of WNT1 expression activity in a G-quadruplex structure dependent manner, we evaluated a series of 6-substituted 9-chloro-11H-indeno[1,2-c]quinolin-11-one derivatives that potentially inhibit the Wnt1-mediated signaling pathway. The most potent compound SJ26 showed repression of WNT1 activity in a G-quadruplex structure-dependent manner. Moreover, compound SJ26 inhibited the WNT1-mediated downstream signaling pathway and suppressed migration activity of cancer cells. Thus, we have identified a tetracyclic azafluorenone, SJ26, that is capable of binding to G-quadruplex DNA structure, repressing WNT1 expression, and inhibiting cell migration.

Indexed as

G-QuadruplexesAntineoplastic AgentsCell Line, TumorCell MovementCell ProliferationDNA, NeoplasmFluorenesGene Expression Regulation, NeoplasticHeterocyclic Compounds, 4 or More RingsHumansMCF-7 CellsMolecular StructureNucleic Acid ConformationPromoter Regions, GeneticWnt1 ProteinWnt Signaling PathwayAntineoplastic AgentsazafluorenoneDNA, NeoplasmFluorenesHeterocyclic Compounds, 4 or More RingsSJ26 compoundWnt1 Protein6-substituted 9-chloro-11H-indeno[1,2-c]quinolin-11-onesG-quadruplexreporter assayWnt1-mediated signaling pathway

Identifiers

PMID27626678
PMCPMC5356533
OpenAlexW2475135667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.